UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response...

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	s)																	
Name and Address of Reporting Person* Scibetta James S				2. Issuer Name and Ticker or Trading Symbol Matinas BioPharma Holdings, Inc. [MTNB]							5	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner							
(Last) (First) (Middle) C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206 SOUTH SUITE 302				3. Date of Earliest Transaction (Month/Day/Year) 06/30/2019							-	Office	r (give title belo	ow)	Other	r (specify be	ow)		
(Street) BEDMINSTER,, NJ 07921				4. If Amendment, Date Original Filed(Month/Day/Year)								6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting PersonForm filed by More than One Reporting Person							
(City)	(State)	(Zip)	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned															
1.Title of Security (Instr. 3)			2. Transaction Date (Month/Day/Year)			ion Date, if		sac 8)	(A	4. Securities Acqui (A) or Disposed of (Instr. 3, 4 and 5)		d of (Benefici Reporte		ount of Securities cially Owned Following ed Transaction(s)		6. Ownership Form: Direct (D)		Beneficial
				(IMO	nth/Day/Y	ear)	Code	e	V A	mount	(A) or (D)	Pri	ice	(Instr. 3 a	na 4)			\ /	Ownership Instr. 4)
Common	Stock		06/30/2019				A		2	1,879)	A	\$	0	577,159			D		
			Table II - I				-	t	he fori	n disposed of	plays a f, or Be	nefic	rren cially	tly valid		spond unle trol numbe			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Y	3A. Deemed Execution Da	4. te, if Transaction Code Year) (Instr. 8)		on 1	5.		(Month/Day/Year)			7 A U S	7. Title and Amount of Underlying Securities (Instr. 3 and 4)		Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	y n(s)	Ownersh Form of Derivating Security Direct (I or Indire	Beneficia Ownershi (Instr. 4)
					Code	V	(A) (E		Date Exercis		Expiration Date	on T	Γitle	or Number of Shares					
Renor	rting ()	wners																	

	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
Scibetta James S C/O MATINAS BIOPHARMA HOLDINGS, INC. 1545 ROUTE 206 SOUTH SUITE 302 BEDMINSTER,, NJ 07921	X						

Signatures

/s/_Jerome D. Jabbour, attorney-in fact for James S. Scibetta	07/02/2019
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) On June 30, 2019, the Reporting Person was issued 21,879 shares of common stock par value \$.0001 per share pursuant to the Company's 2013 Equity Compensation Plan. Such shares vest immediately upon grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.